Information for Healthcare Professionals
FORCE supports healthcare professionals
If you're a healthcare professional caring for individuals and families affected by hereditary cancer, FORCE has evidence-informed tools, education and support resources to facilitate shared decision-making, and compassionate, informed care to help.
Help Your Patients Find Support
FORCE support programs include virtual community meetings, trained guidance from peer navigators and community message boards. We offer your patients multiple ways to connect with others in a safe, supportive environment. Download our flyer with all our support programs.
Support Meetings & Events
FORCE's Support Meetings and Events Calendar provides details on upcoming support meetings, webinars and partner events.
1 to 1 Support & Navigation
FORCE's Peer Navigation Program connects those seeking support with a trained peer navigator who shares a similar experience.
Spotlight
Looking for the latest guidelines?
FORCE provides gene-specific summaries on cancer risk, screening, prevention and treatment guidelines, and resources for individuals with inherited cancer risk.
Customizable Resources
Add your logo and contact info to FORCE materials
FORCE’s resource center allows you to personalize FORCE publications and genetic test result disclosure letters with your contact information and logo for printing or sharing on demand. We also provide links and QR codes to curated content for specific genes, which you can use within your own materials.
Insurance Coverage & Appeals
Find information on insurance coverage and reimbursement for health insurance appeals. Our customizable insurance appeal letters are designed to help you and your patients quickly appeal insurance denials.
Find Research Studies Enrolling People with Inherited Mutations
Use our search and enroll tool to connect your patients to the latest cancer prevention, treatment and quality-of-life studies enrolling people with or at high risk for hereditary cancers.
This study tests whether COM701 (an anti‑PVRIG immunotherapy) given every 3 weeks as maintenance can delay cancer growth after a good response to platinum chemotherapy. Adults with relapsed platinum‑sensitive ovarian, fallopian tube, or primary peritoneal...
ADHERE: Survey about Pancreatic Cancer Screening Options for People with Inherited Risk
The purpose of this study is to understand knowledge and opinions about pancreatic cancer screening, access to and decision-making around screening, and how a blood-based test might influence screening among individuals with inherited (germline) mutations...
The FourLight-3 clinical trial compares a study treatment, atrimociclib combined with letrozole, against standard approved treatments. The clinical trial is for adults with advanced or metastatic HR-positive, HER2-negative breast cancer who have not received prior...
Go Behind the Headlines
Force's XRAY program shares easy-to-understand information on the latest cancer research.
Update : Promising FDA updates in ovarian cancer
This update highlights recent FDA news focused on ovarian cancer, including a new treatment option and two promising investigational drugs that received the FDA’s Breakthrough Therapy designation. These updates may provide more treatment choices for...
Study : Treating advanced breast cancer with ESR1 mutations shows promise
Treatment with the new hormonal drug camizestrant benefited people with certain advanced breast cancers with a biomarker called an ESR1 mutation. People who participated in the SERENA6 study experienced a longer time before their cancer...
Update : News from the FDA on metastatic prostate cancer treatment
This update highlights recent FDA approvals and expanded uses for three drugs related to metastatic prostate cancer treatment. These updates affect how prostate cancer may be found and treated, including new options that may allow...
Quickly share FORCE resources with just a few clicks!
FORCE’s Healthcare Provider Toolkit makes it easy to distribute resources across your favorite social media platforms.